Calithera Biosciences (NASDAQ:CALA) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALAGet Rating) in a research note published on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

CALA has been the topic of a number of other research reports. LADENBURG THALM/SH SH dropped their price objective on Calithera Biosciences from $3.00 to $1.50 in a research note on Wednesday, May 11th. Zacks Investment Research lowered Calithera Biosciences from a buy rating to a hold rating in a research report on Tuesday, April 12th. Finally, SVB Leerink cut their target price on Calithera Biosciences from $3.00 to $2.00 and set an outperform rating on the stock in a research report on Monday, April 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, Calithera Biosciences presently has an average rating of Hold and a consensus target price of $2.00.

Shares of CALA stock opened at $0.21 on Friday. Calithera Biosciences has a 1 year low of $0.15 and a 1 year high of $2.59. The stock has a fifty day moving average of $0.31 and a two-hundred day moving average of $0.51.

Calithera Biosciences (NASDAQ:CALAGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.18). During the same period last year, the business posted ($0.28) EPS. Equities analysts expect that Calithera Biosciences will post -0.59 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC grew its stake in Calithera Biosciences by 1,090.8% in the fourth quarter. Acadian Asset Management LLC now owns 1,856,730 shares of the biotechnology company’s stock valued at $1,234,000 after purchasing an additional 1,700,803 shares in the last quarter. Tudor Investment Corp Et Al bought a new stake in shares of Calithera Biosciences during the 3rd quarter worth about $59,000. BVF Inc. IL boosted its stake in shares of Calithera Biosciences by 2.1% during the 3rd quarter. BVF Inc. IL now owns 7,452,331 shares of the biotechnology company’s stock worth $16,246,000 after acquiring an additional 153,000 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of Calithera Biosciences by 2.6% during the 3rd quarter. Primecap Management Co. CA now owns 10,608,700 shares of the biotechnology company’s stock worth $23,127,000 after acquiring an additional 265,000 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of Calithera Biosciences by 1,031.8% during the 3rd quarter. Two Sigma Investments LP now owns 200,323 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 182,623 shares in the last quarter. Hedge funds and other institutional investors own 55.84% of the company’s stock.

Calithera Biosciences Company Profile (Get Rating)

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology.

Featured Articles

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.